Pharmacokinetic and pharmacodynamic variability: A daunting challenge in drug therapy

被引:52
作者
Lin, Jiunn H. [1 ]
机构
[1] Merck Sharp & Dohme Ltd, Res Labs, Dept Preclin Drug Metab, West Point, PA 19486 USA
关键词
D O I
10.2174/138920007779816002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Patients vary considerably in their response to drug therapy. A drug that proves to be pharmacologically effective in some patients at a given dose may be ineffective or even toxic in others. The interindividual variability in drug response represents a major challenge in drug therapy, particularly for drugs with narrow therapeutic index. The intensity and duration of a drug action are determined not only by pharmacokinetic processes, but also by pharmacodynamic processes. Therefore, the variability in drug response is a result of the variability in either pharmacokinetic or pharmacodynamic processes, or a combination of both. The purpose of this paper is to review the sources that contribute to pharmacokinetic and pharmacodynamic variability. Although the main focus will be on the genetic variability, the impact of environmental factors on drug response will also be discussed. Finally, the application and limitation of the concept of personalized medicine will be briefly discussed.
引用
收藏
页码:109 / 136
页数:28
相关论文
共 328 条
[1]   The personalized medicine coalition - Goals and strategies [J].
Abrahams, E ;
Ginsburg, GS ;
Silver, M .
AMERICAN JOURNAL OF PHARMACOGENOMICS, 2005, 5 (06) :345-355
[2]   Angiotensin converting enzyme I/D, angiotensinogen T174M-M235T and angiotensin II type 1 receptor A1166C gene polymorphisms in Turkish hypertensive patients [J].
Agachan, B ;
Isbir, T ;
Yimaz, H ;
Akoglu, E .
EXPERIMENTAL AND MOLECULAR MEDICINE, 2003, 35 (06) :545-549
[3]  
Aklillu E, 1996, J PHARMACOL EXP THER, V278, P441
[4]  
ALHENCGELAS F, 1991, J LAB CLIN MED, V117, P33
[5]   INTRAINDIVIDUAL VARIATION IN DRUG DISPOSITION [J].
ALVARES, AP ;
KAPPAS, A ;
EISEMAN, JL ;
ANDERSON, KE ;
PANTUCK, CB ;
PANTUCK, EJ ;
HSIAO, KC ;
GARLAND, WA ;
CONNEY, AH .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1979, 26 (04) :407-419
[6]   POLYMORPHIC HYDROXYLATION OF S-MEPHENYTOIN AND OMEPRAZOLE METABOLISM IN CAUCASIAN AND CHINESE SUBJECTS [J].
ANDERSSON, T ;
REGARDH, CG ;
LOU, YC ;
ZHANG, Y ;
DAHL, ML ;
BERTILSSON, L .
PHARMACOGENETICS, 1992, 2 (01) :25-31
[7]  
Ando Y, 2000, CANCER RES, V60, P6921
[8]  
[Anonymous], PREVENTION TREATMENT
[9]   ASSOCIATION BETWEEN CLOZAPINE RESPONSE AND ALLELIC VARIATION IN 5HT(2A) RECEPTOR GENE [J].
ARRANZ, M ;
COLLIER, D ;
SODHI, M ;
BALL, D ;
ROBERTS, G ;
PRICE, J ;
SHAM, P ;
KERWIN, R .
LANCET, 1995, 346 (8970) :281-282
[10]   Pharmacogenetic prediction of clozapine response [J].
Arranz, MJ ;
Munro, J ;
Birkett, J ;
Bolonna, A ;
Mancama, D ;
Sodhi, M ;
Lesch, KP ;
Meyer, JFW ;
Sham, P ;
Collier, DA ;
Murray, RM ;
Kerwin, RW .
LANCET, 2000, 355 (9215) :1615-1616